Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2021-10-15
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Value of Metagenomic Sequencing in Neonatal Sepsis
NCT05416918
Assessment of New Blood Culture Methods on the Microbiological Documentation of Febrile Neutropenia
NCT00913042
Using of Biomarkers and Blood Culture in Early Detection of Systemic Infections
NCT05737537
Economic Impact of mNGS on Diagnosis of Post-neurosurgical Central Nervous System Infection
NCT05887037
Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections
NCT00709358
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood culture versus mNGS detection
peripheral 4ml for mNGS detection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* febrile neutropenia
Exclusion Criteria
* age\<=14
* not caused by infection
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University First Hospital
OTHER
Peking University International Hospital
OTHER
Hebei Yanda Ludaopei Hospital
OTHER
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiao-Jun Huang
Head of Peking University Institute of Hematology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
YUQIAN SUN, MD
Role: PRINCIPAL_INVESTIGATOR
Peiking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yuqian Sun
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
mNGS for FN(2021PHB362-001)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.